AIM ImmunoTech (NYSEAMERICAN:AIM) Posts Quarterly Earnings Results

AIM ImmunoTech (NYSEAMERICAN:AIM) issued its earnings results on Friday. The company reported ($0.43) earnings per share for the quarter, FiscalAI reports. The firm had revenue of $0.03 million during the quarter.

AIM ImmunoTech Stock Performance

AIM ImmunoTech stock traded up $0.01 during trading hours on Friday, reaching $0.29. 968,259 shares of the company were exchanged, compared to its average volume of 13,541,045. AIM ImmunoTech has a 12 month low of $0.21 and a 12 month high of $2.98. The firm has a market cap of $4.16 million, a price-to-earnings ratio of -0.04 and a beta of 1.20. The stock has a 50-day moving average of $0.35 and a 200 day moving average of $0.60. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 0.10.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in AIM ImmunoTech stock. Corient Private Wealth LLC bought a new position in shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 10,001 shares of the company’s stock, valued at approximately $87,000. Corient Private Wealth LLC owned approximately 1.31% of AIM ImmunoTech at the end of the most recent quarter. Institutional investors own 12.02% of the company’s stock.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets decreased their price objective on shares of AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, AIM ImmunoTech presently has a consensus rating of “Buy” and an average target price of $9.00.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.